Literature DB >> 12433820

Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10.

Yuichiro Watanabe1, Miki Nakajima, Tsuyoshi Yokoi.   

Abstract

Troglitazone glucuronidation in human liver and intestine microsomes and recombinant UDP-glucuronosyltransferases (UGTs) were thoroughly characterized. All recombinant UGT isoforms in baculovirus-infected insect cells (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) exhibited troglitazone glucuronosyltransferase activity. Especially UGT1A8 and UGT1A10, which are expressed in extrahepatic tissues such as stomach, intestine, and colon, showed high catalytic activity, followed by UGT1A1 and UGT1A9. The kinetics of the troglitazone glucuronidation in the recombinant UGT1A10 and UGT1A1 exhibited an atypical pattern of substrate inhibition when the substrate concentration was over 200 micro M. With a Michaelis-Menten equation at 6 to 200 micro M troglitazone, the K(m) value was 11.1 +/- 5.8 micro M and the V(max) value was 33.6 +/- 3.7 pmol/min/mg protein in recombinant UGT1A10. In recombinant UGT1A1, the K(m) value was 58.3 +/- 29.2 micro M and the V(max) value was 12.3 +/- 2.5 pmol/min/mg protein. The kinetics of the troglitazone glucuronidation in human liver and jejunum microsomes also exhibited an atypical pattern. The K(m) value was 13.5 +/- 2.0 micro M and the V(max) value was 34.8 +/- 1.2 pmol/min/mg for troglitazone glucuronidation in human liver microsomes, and the K(m) value was 8.1 +/- 0.3 micro M and the V(max) was 700.9 +/- 4.3 pmol/min/mg protein in human jejunum microsomes. When the intrinsic clearance was estimated with the in vitro kinetic parameter, microsomal protein content, and weight of tissue, troglitazone glucuronidation in human intestine was 3-fold higher than that in human livers. Interindividual differences in the troglitazone glucuronosyltransferase activity in liver microsomes from 13 humans were at most 2.2-fold. The troglitazone glucuronosyltransferase activity was significantly (r = 0.579, p < 0.05) correlated with the beta-estradiol 3-glucuronosyltransferase activity, which is mainly catalyzed by UGT1A1. The troglitazone glucuronosyltransferase activity in pooled human liver microsomes was strongly inhibited by bilirubin (IC(50) = 1.9 micro M), a typical substrate of UGT1A1. These results suggested that the troglitazone glucuronidation in human liver would be mainly catalyzed by UGT1A1. Interindividual differences in the troglitazone glucuronosyltransferase activity in S-9 samples from five human intestines was 8.2-fold. The troglitazone glucuronosyltransferase activity in human jejunum microsomes was strongly inhibited by emodin (IC(50) = 15.6 micro M), a typical substrate of UGT1A8 and UGT1A10, rather than by bilirubin (IC(50) = 154.0 micro M). Therefore, it is suggested that the troglitazone glucuronidation in human intestine might be mainly catalyzed by UGT1A8 and UGT1A10.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433820     DOI: 10.1124/dmd.30.12.1462

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.

Authors:  Jacqueline Ramírez; Snezana Mirkov; Larry K House; Mark J Ratain
Journal:  Drug Metab Dispos       Date:  2015-04-13       Impact factor: 3.922

Review 2.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver.

Authors:  Yuji Mano; Takashi Usui; Hidetaka Kamimura
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

4.  Contributions of Hepatic and Intestinal Metabolism to the Disposition of Niclosamide, a Repurposed Drug with Poor Bioavailability.

Authors:  Xiaoyu Fan; Hongmin Li; Xinxin Ding; Qing-Yu Zhang
Journal:  Drug Metab Dispos       Date:  2019-04-30       Impact factor: 3.922

5.  Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.

Authors:  Kyunghee Yang; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2014-05-05       Impact factor: 3.922

6.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

7.  Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation.

Authors:  Jin Kyung Lee; Tracy L Marion; Koji Abe; Changwon Lim; Gary M Pollock; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2009-10-02       Impact factor: 4.030

Review 8.  Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.

Authors:  Xiaomin Deng; James P Luyendyk; Patricia E Ganey; Robert A Roth
Journal:  Pharmacol Rev       Date:  2009-09       Impact factor: 25.468

9.  Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population.

Authors:  Oliwia Zakerska; Marzena Skrzypczak-Zielinska; Adam Mikstacki; Barbara Tamowicz; Bianka Malengowska; Marlena Szalata; Ryszard Slomski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-11-25       Impact factor: 2.441

10.  Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs.

Authors:  Melissa Runge-Morris; Thomas A Kocarek
Journal:  PPAR Res       Date:  2009-08-10       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.